Date: 17 Sep 2012
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
Sugammadex (Bridion®), a modified γ-cyclodextrin, is the first selective relaxant binding agent indicated to reverse the neuromuscular blockade induced during general anaesthesia to facilitate surgical procedures. The mechanism of action of sugammadex differs from that of other commonly used reversal agents, such as neostigmine and edrophonium. In the EU, sugammadex is recommended for use in the reversal of rocuronium- or vecuronium-induced moderate or deep muscle relaxation in adult (including elderly) patients and reversal of rocuronium-induced moderate muscle relaxation in paediatric patients (aged 2–17 years). Sugammadex is also approved in Australia, Iceland, New Zealand and Norway.
In clinical trials in adult surgical patients with relatively good health, sugammadex at recommended doses provided rapid reversal of rocuronium- or vecuronium-induced neuromuscular blockade with a low incidence of residual or recurrent neuromuscular blockade and was generally well tolerated. In paediatric patients, sugammadex effectively reversed rocuronium-induced neuromuscular blockade and was generally well tolerated. Several factors associated with the use of sugammadex have yet to be determined, such as the efficacy and safety in patients with poorer health or in those with neuromuscular disorders, the incidence of infrequent adverse events in larger patient populations and the cost effectiveness of the drug relative to existing reversal agents. Nevertheless, sugammadex is a useful addition to the reversal agents commonly employed in anaesthetic practice.
Sugammadex encapsulates and inactivates rocuronium; it selectively binds to free rocuronium molecules with high affinity at a molar ratio of 1:1. The resulting inactive complex is eliminated from the body according to the pharmacokinetic properties of sugammadex. Sugammadex also has high affinity for vecuronium. In several phase I and II trials, sugammadex demonstrated dose-dependent reversal of rocuronium- or vecuronium-induced blockade when administered at the reappearance of the second twitch of the train-of-four stimulation (T2) or at a post-tetanic count of 1–2 (1–2 PTC), or 3–15 minutes after the administration of the neuromuscular blocking agent. Sugammadex has no clinically relevant effects on the cardiovascular and haemodynamic systems (including corrected QT interval prolongation).
Intravenous sugammadex demonstrates linear pharmacokinetic properties over the dose range of 1–16 mg/kg. The steady-state volume of distribution after a single dose is ≈1-14 L. Sugammadex and the sugammadex-rocuronium complex do not bind to plasma proteins or erythrocytes. Sugammadex does not appear to undergo metabolism and is primarily excreted in the urine as unchanged drug; the elimination half-life is 1.8 hours. Administration of sugammadex following that of rocuronium increases the plasma concentration of rocuronium (in a manner dependent on the dose of sugammadex), shortens its elimination half-life (by ≈30%) and increases the urinary excretion (by 2- to 3-fold) of rocuronium; however, these changes are not associated with an increase in the level of neuro-muscular blockade. Unlike rocuronium, the sugammadex-rocuronium complex is not eliminated via the biliary route. Renal impairment (but not hepatic impairment or patient age) delays the elimination of sugammadex and the sugammadex-rocuronium complex, and the use of sugammadex in patients with severe renal impairment is not recommended.
The efficacy of sugammadex has been evaluated in several well designed phase III trials in adult (including elderly) or paediatric surgical patients. In adult patients, sugammadex 2 mg/kg reversed rocuronium 0.6 mg/kg or vecuronium O.l mg/kg significantly faster than neostigmine 50 μg/kg plus glycopyrrolate 10 μg/kg, when administered at the reappearance of T2. In addition, the reversal of rocuronium 0.6 mg/kg by sugammadex 2 mg/kg was significantly faster than the reversal of cisatracurium 0.15 mg/kg by neostigmine 50μg/kg plus glycopyrrolate 10μg/kg. Sugammadex 4 mg/kg reversed rocuronium 0.6 mg/kg or vecuronium 0.1 mg/kg significantly faster than neostigmine 70 μg/kg plus glycopyrrolate 14 μg/kg, when administered at 1–2 PTC. When administered 3 minutes after rocuronium, sugammadex 16 mg/kg reversed rocuronium 1.2 mg/kg significantly faster than the spontaneous recovery after suxamethonium chloride (succinylcholine).
The time to reverse neuromuscular blockade with sugammadex 2 mg/kg administered at the reappearance of T2 following rocuronium 0.6 mg/kg was slower in elderly than in younger adult patients; however, reversal was reached in <4 minutes in the majority (75.5%) of elderly patients. In infants, children, adolescents and adults receiving sugammadex 2 mg/kg following rocuronium 0.6 mg/kg, the mean time to neuromuscular blockade reversal was <1.9 minutes. The efficacy of sugammadex 2 mg/kg did not differ between patients with normal renal function and those with severe renal impairment. Underlying cardiac or pulmonary disease had no effect on the efficacy of sugammadex.
Sugammadex was generally well tolerated in clinical trials in surgical patients (including elderly or paediatric patients, or patients with renal impairment or cardiac or pulmonary disease) or healthy volunteers. The majority of adverse events considered to be related to sugammadex were mild to moderate in severity. The most commonly reported adverse events in any study group were procedural pain, nausea and vomiting. In pooled analyses, the tolerability profile of sugammadex was generally similar to that of placebo or neostigmine plus glycopyrrolate; serious adverse events were infrequent. Uncommon adverse events include anaesthetic complications and dysgeusia in awake healthy volunteers, which were more frequent with higher than recommended doses of sugammadex (≥16 mg/kg), and residual or recurrent neuromuscular blockade which was more frequent with lower than recommended doses of sugammadex (<2mg/kg).
Various sections of the manuscript reviewed by: A.R. Aitkenhead, University Department of Anaesthesia, Queen’s Medical Centre, Nottingham, England; K. Khuenl-Brady, Department of Anaesthesia and General Intensive Care Medicine, Medical University Innsbruck, Innsbruck, Austria; S. J. Brull, Department of Anesthesiology, Mayo Clinic College of Medicine, Jacksonville, Florida, USA; F. Donati, Department of Anesthesiology, University of Montreal, Montreal, Quebec, Canada; S.B. Groudine, Department of Anesthesiology, Albany Medical Center, Albany, New York, USA; R.K. Mirakhur, Department of Anaesthetics and Intensive Care Medicine, Queen’s University, Belfast, Northern Ireland; W.T. Nicholson, Department of Anesthesiology, College of Medicine, Mayo Clinic, Rochester, Minnesota, USA.
Sources: Medical literature published in any language since 1980 on ‘sugammadex’, identified using MEDLINE and EMBASE, supplemented by AdisBase (a proprietary database of Wolters Kluwer Health | Adis). Additional references were identified from the reference lists of published articles. Bibliographical information, including contributory unpublished data, was also requested from the company developing the drug.
Search strategy: MEDLINE, EMBASE and AdisBase search terms were ‘sugammadex’ or ‘ORG-25969’. Searches were last updated 7 May 2009.
Selection: Studies in patients undergoing surgery who received sugammadex. Inclusion of studies was based mainly on the methods section of the trials. When available, large, well controlled trials with appropriate statistical methodology were preferred. Relevant pharmacodynamic and pharmacokinetic data are also included.
Index terms: Sugammadex, selective relaxant binding agent, pharmacodynamics, pharmacokinetics, therapeutic use, tolerability.
de Boer HD, van Egmond J, Driessen JJ, et al. Update on the management of neuromuscular block: focus on su-gammadex. Neuropsych Dis Treat 2007; 3(5): 539–44
GlaxoSmithKline UK. Anectine injection (suxamethonium chloride): summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/displayDocPrinterFriendly.asp?documentid=704 [Accessed 2008 Sep 26]
NV Organon. Esmeron® (rocuronium bromide) 10mg/mL solution for injection: summary of product characteristics [online]. Available from URL: http://emc.medicines.org.uk/emc/assets/c/html/displayDocPrinterFriendly.asp?documentid=5166 [Accessed 2008 Oct 9]
Schering-Plough Corp. Bridion® (sugammadex sodium) injection: first and only selective relaxant binding agent approved in European Union [online]. Available from URL: http://www.schering-plough.com/schering_plough/news/release.jsp?releaseID=1180933 [Accessed 2008 Aug 20]
Zhang M-Q. Drug-specific cyclodextrins: the future of rapid neuromuscular block reversal? Drugs Future 2003 Apr; 28(4): 347–54CrossRef
Epemolu O, Mayer I, Hope F, et al. Liquid chrom-atography/mass spectrometric bioanalysis of a modified γ-cyclodextrin (Org 25969) and rocuronium bromide (Org 9426) in guinea pig plasma and urine: its application to determine the plasma pharmacokinetics of Org 25969. Rapid Commun Mass Spectrom 2002; 16(20): 1946–52PubMedCrossRef
Pühringer FK, Rex C, Sielenkämper AW, et al. Reversal of profound, high-dose rocuronium-induced neuromuscular blockade by sugammadex at two different time points: an international, multicenter, randomized, dose-finding, safety assessor-blinded, phase II trial. Anesthesiology 2008 Aug; 109(2): 188–97PubMedCrossRef
Wagner S, Pühringer FK, Spies C, et al. Sugammadex reverses neuromuscular blockade after continuous infusion of rocuronium in patients under sevoflurane or propofol maintenance anesthesia [abstract no. S218]. Anesth Analg 2008 Mar; 106 Suppl. 3: S218
European Medicines Agency. Bridion (sugammadex sodium) 100 mg/mL: summary of product characteristics [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/bridion/H-885-PI-en.pdf [Accessed 2009 Feb 5]
de Kam P-J, van Kuijk J, Smeets J, et al. Single IV sugammadex doses up to 32 mg/kg are not associated with QT/QTc prolongation [abstract no. A1580]. 2007 Annual Meeting of the American Society of Anesthesiologists; 2007 Oct 13–17; San Francisco (CA)
de Kam P, van Kuijk J, Prohn M, et al. Single IV sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium are not associated with QTc prolongation [abstract no. 9AP5-9]. Eur J Anaes-thesiol 2008 Jun; 25 Suppl. 44: 9AP5–9. Plus poster presented at the 2008 Annual Meeting of the European Society of Anaesthesiology; 2008 May 31–Jun 3; Copenhagen
Organon USA. FDA Anesthetic and Life Support Advisory Committee Meeting: briefing document (background package) for sugammadex sodium injection [online]. Available from URL: http://www.fda.gov/ohrms/dockets/ac/08/briefing/2008-4346bl-02-Organon.pdf [Accessed 2008 Oct 2]
American Society of Anesthesiologists. ASA physical status classification system [online]. Available from URL: http://www.asahq.org/clinical/physicalstatus.htm [Accessed 2008 Sep 26]
International Conference on Harmonisation of Technical Requirements for Registration of Pharmaceuticals for Human Use. The clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs: E14 [online]. Available from URL: http://www.ich.org/LOB/media/MEDIA1476.pdf [Accessed 2009 Apr 6]
Dahl V, Pendeville PE, Hollman MW, et al. Reversal of rocuronium-induced neuromuscular blockade by sugammadex in cardiac patients [abstract no. A1581 plus poster]. 2007 Annual Meeting of the American Society of Anesthesiologists; 2007 Oct 13–17; San Francisco (CA)
Staals L, Snoeck M, Hunter J, et al. Pharmacokinetics of rocuronium and sugammadex in patients with normal and impaired renal function [abstract plus poster]. 14th World Congress of Anaesthesiologists; 2008 Mar 2–7; Cape Town
Proost JH, Eriksson LI, Mirakhur RK, et al. Urinary, biliary and faecal excretion of rocuronium in humans. Br J An-aesth 2000 Nov; 85(5): 717–23
Plaud B, Meretoja O, Hofmockel R, et al. Reversal of ro-curonium-induced neuromuscular blockade with sugammadex in pediatric and adult surgical patients. Anesthesiology 2009 Feb; 110(2): 284–94PubMed
Blobner M, Eriksson L, Scholz J, et al. Sugammadex (2.0 mg/kg) significantly faster reverses shallow rocuronium-induced neuromuscular blockade compared with neostigmine (50mg/kg) [abstract no. 9AP7-10]. Eur J Anaesthesiol 2007 Jun; 24: 125. Plus poster presented at the 2007 Congressof the European Society of Anaesthesiology; 2007 Jun 9–12; MunichCrossRef
Alvarez-Gómez JA, Wattwill M, Vanacker B, et al. Reversal of vecuronium-induced shallow neuromuscular blockade is significantly faster with sugammadex compared with neostigmine [abstract no. 9AP7-8]. Eur J Anaesthesiol 2007 Jun; 24 Suppl. 39: 124–5. Plus poster presented at the 2007 Congress of the European Society of Anaesthesiology; 2007 Jun 9–12; MunichCrossRef
Lemmens HJM, El-Orbany MI, Berry J, et al. Sugammadex reverses profound vecuronium blockade more rapidly than neostigmine [abstract no. A1578 plus poster]. 2007 Annual Meeting of the American Society of Anesthesiologists; 2007 Oct 13–17; San Francisco (CA)
Pavlin EG, White PF, Viegas OJ, et al. Sugammadex given at least 15 min after rocuronium is effective in reversing neuromuscular blockade [abstract no. A1579 plus poster]. 2007 Annual Meeting of the American Society of Anesthesiologists; 2007 Oct 13–17; San Francisco (CA)
McDonagh DL, Benedict PE, Kovac AL, et al. Efficacy and safety of sugammadex for reversal of rocuronium-induced blockade in elderly patients [abstract no. A1583 plus poster]. 2007 Annual Meeting of the American Society of Anesthesiologists; 007 Oct 13–17; San Francisco (CA)
Amao R, Zornow MH, McTaggart Cowan R, et al. Sugammadex safely reverses rocuronium-induced blockade in patients with pulmonary disease [abstract no. A1582 plus poster]. 2007 Annual Meeting of the American Society of Anesthesiologists; 2007 Oct 13–17; San Francisco (CA)
Monk TG, Rietbergen H, Woo T. Obesity has no clinically relevant impact upon recovery time following administration of sugammadex [abstract no. A682 plus poster]. 2008 Annual Meeting of the American Society of Anesthesiologists; 2008 Oct 18–22; Orlando (FL)
Peeters P, Passier P, Smeets J, et al. Single intravenous high-dose sugammadex (up to 96 mg/kg) is generally safe and well tolerated in healthy volunteers [abstract no. 9AP3-6]. Eur J Anaesthesiol 2008; 25 Suppl. 4: 9AP3–6. Plus poster presented at the 2008 Congress of the European Society of Anaesthesiology; 2008 May 31–Jun 3; Copenhagen
European Medicines Agency. European Public Assessment Report for Bridion (sugammadex): scientific discussion [online]. Available from URL: http://www.emea.europa.eu/humandocs/PDFs/EPAR/bridion/H-885-en6.pdf [Accessed 2008 Oct 1]
Plaud B, van Heumen E, Zwiers A. Sugammadex is well tolerated for the reversal of rocuronium- or vecuronium-induced neuromuscular blockade in a pooled analysis of adverse events in 10 placebo-controlled trials [abstract no. 9AP3-3]. Eur J Anaesthesiol 2008; 25 Suppl. 44: 9AP3–3. Plus poster presented at the 2008 Congress of the European Society of Anaesthesiology; 2008 May 31–Jun 3; Copenhagen
Donati F. Sugammadex: a cyclodextrin to reverse neuromuscular blockade in anaesthesia. Expert Opin Pharmac-other 2008 May; 9(8): 1375–86CrossRef
Murphy GS. Residual neuromuscular blockade: incidence, assessment, and relevance in the postoperative period. Minerva Anestesiol 2006 Mar; 72(3): 97–109PubMed
Harris AM, Welliver M, Redfern R, et al. Orthopaedic surgery implications of a novel encapsulation process that improves neuromuscular blockade and reversal. Internet J Orthop Surg 2007; 7(2): el–12
Duvaldestin P, Kuizenga K, Kjaer CC, et al. Sugammadex achieves fast recovery from profound neuromuscular blockade induced by rocuronium or vecuronium: a dose-response study [abstract no. 9AP7-3]. Eur J Anaesthesiol 2007 Jun; 24: 123. Plus poster presented at the 2007 Congress of the European Society of Anaesthesiology; 2007 Jun 9–12; MunichCrossRef
Perry JJ, Lees JS, Sillberg VA, et al. Rocuronium versus succinylcholine for rapid sequence induction intubation. Cochrane Database Syst Rev 2008 Apr 16; 16(2): CD002788
Zhang B, Menzin J, Tran MH, et al. The potential savings in operating room time associated with the use of sugammadex to reverse selected neuromuscular blocking agents: findings from a hospital efficiency model [abstract no. PHC9]. Value Health 2008 May–Jun; 11(3): A244CrossRef
Schering-Plough Corp. US FDA issues action letter for sugammadex [online]. Available from URL: http://www.schering-plough.com/schering_plough/news/release.jsp?releaseID=1182475 [Accessed 2008 Aug 20]
Volume 69, Issue 7 , pp 919-942
- Cover Date
- Print ISSN
- Online ISSN
- Springer International Publishing
- Additional Links
- Industry Sectors